Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC0062 in CKD with Albuminuria
NCT05687890Phase 2Active, not recruiting
- Sponsor
- BioCity Biopharma
- Start
- May 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SC0062 in diabetic kidney disease (DKD) and IgA nephropathy (IgAN) (4 arms), sponsored by BioCity Biopharma. Primary endpoints: Change in urine albumin creatinine ratio at 12 weeks and Change in urine protein creatinine ratio at 12 weeks. Started May 2023; status: active, not recruiting.
02
Drugs
SC0062
03
Conditions
diabetic kidney disease (DKD)IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT05687890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05687890.